ILMN Stock Set to Benefit From the Launch of New BioInsight Division
Illumina launches BioInsight to harness multiomic data, accelerate drug discovery, and boost disease diagnosis.
ANGO Stock Gains Following Q1 Earnings Beat, Gross Margin Improves
AngioDynamics posts narrower-than-expected Q1 loss, 12% revenue growth and margin gains. it also raises FY26 sales outlook, sending shares higher.
CorMedix Announces Completion of Enrollment in Phase III ReSPECT Clinical Trial for REZZAYO
- Enrollment Completed in Ongoing Phase III ReSPECT Study in Prophylaxis of Fungal Infections in Adult Patients Undergoing Allogeneic Blood and Marrow Transplant ...
CDTX Stock Soars 218% YTD on Positive Updates From Influenza Program
Cidara Therapeutics' shares surge 218% this year after its flu candidate CD388 hits key mid-stage study goals and advances into pivotal testing.
QURE Stock Skyrockets on Meeting Goals in Huntington's Disease Study
uniQure N.V. shares surge nearly 248% after its gene therapy candidate, AMT-130, met key goals in a pivotal Huntington's disease study.
ACAD Stock Down 10% Following Phase III Hyperphagia Study Failure
Acadia Pharmaceuticals stock tumbles 10% after its phase III hyperphagia study failure, but growth remains driven by Nuplazid, Daybue and a robust pipeline.
REPL Stock Plunges 54% in 3 Months After FDA Rejects Skin Cancer Drug
Replimune stock dives 54% over three months after the FDA rejects its RP1/Opdivo melanoma drug filing, delaying its first potential product launch.
CRMD vs. MIRM: Which Specialized Biotech Stock is the Better Pick?
CorMedix and Mirum Pharmaceuticals are advancing niche therapies with strong launches, rising sales and strategic acquisitions shaping their growth.
SNY & REGN's Dupixent Receives CHMP Backing for Urticaria in EU
Sanofi/Regeneron's Dupixent wins CHMP backing for chronic spontaneous urticaria in the EU, paving the way for expanded treatment options.
FDA Extends Review Period of Sanofi's Multiple Sclerosis Drug Filing
The FDA extends SNY's tolebrutinib NDA review by three months, with decision now expected on Dec. 28, 2025.
Insider Decision Making Waves At Cormedix: Gregory Scott Duncan Exercises Options, Realizing $45K - Cormedix ( NASDAQ:CRMD )
Highlighted on September 19, it was unveiled in an SEC filing that Duncan, Director at Cormedix CRMD, executed a significant transaction involving the exercise of company stock options. What Happened: A notable Form 4 filing on Friday with the U.S.
Can CorMedix's Melinta Deal Fuel Growth Via Portfolio Diversification?
CRMD's $300M Melinta buy adds seven therapies, easing reliance on DefenCath sales and bolstering growth in hospital-focused markets.
Biogen Gets EU Nod for First Postpartum Depression Drug
BIIB secures EU approval for Zurzuvae, the first oral treatment for postpartum depression, boosting its long-term growth prospects.
INCY Announces New Late-Stage Data on Skin Disease Drug
Incyte's povorcitinib shows strong 24-week STOP-HS data in hidradenitis suppurativa, supporting 2025-2026 regulatory filings.
PBYI Surges 30% in 3 Months: How Should You Play the Stock?
Puma Biotechnology shares rise nearly 30% in three months on rising Nerlynx sales, with key data on pipeline drug alisertib due later this year.
CorMedix Rallies 60% YTD: Is This an Indication to Buy the Stock?
CRMD stock surges nearly 60% YTD as DefenCath drives strong sales, boosted by a $300M Melinta acquisition deal and raised revenue outlook.
Zoetis Gains CVMP Backing for Portela, Eyes EU Approval in Cat OA Pain
ZTS secures CVMP's positive opinion recommending the approval of Portela, a long-acting OA pain therapy for cats, with final decision expected in late 2025.
JNJ Seeks EU Approval for Oral Psoriasis Drug Icotrokinra
J&J seeks EMA's nod to icotrokinra for treating plaque psoriasis in adults and pediatric patients aged 12 years and older.
RAPP Stock Soars 62% in a Week on Meeting Phase II Epilepsy Study Goal
Rapport Therapeutics stock jumps 62% in a week as mid-stage study of RAP-219 meets goals in drug-resistant epilepsy patients.
Strategic Sale: Elizabeth Hurlburt Decides To Exercise Options Worth $635K At Cormedix - Cormedix ( NASDAQ:CRMD )
In a new SEC filing on September 12, it was revealed that Hurlburt, Chief Operating Officer at Cormedix CRMD, executed a significant exercise of company stock options. What Happened: Disclosed in a Form 4 filing on Friday with the U.S.
Major Exercise Alert: Beth Zelnick Kaufman Exercises Options Worth $495K At Cormedix - Cormedix ( NASDAQ:CRMD )
In a new SEC filing on September 12, it was revealed that Kaufman, Chief Legal Officer at Cormedix CRMD, executed a significant exercise of company stock options. What Happened: Disclosed in a Form 4 filing on Friday with the U.S.
TVTX Stock Soars as FDA Waives Advisory Committee for Filspari sNDA
Travere Therapeutics stock jumps after the FDA drops advisory meeting for Filspari's FSGS filing, with approval decision due in January 2026.
RARE Reports Positive Long-Term Data From Metabolic Disorder Study
Ultragenyx posts 96-week data showing DTX401 sharply cuts cornstarch needs and improves life quality in GSDIa patients.
CorMedix ( CRMD ) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
After losing some value lately, a hammer chart pattern has been formed for CorMedix (CRMD), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.
IMVT Stock Up 11% on Upbeat Batoclimab Hyperthyroidism Study Results
Immunovant stock jumps 11% after new batoclimab study results showed durable thyroid hormone control in Graves' disease patients.
Cytokinetics Gains on Positive Late-Stage Cardiomyopathy Study Results
CYTK shares soar 40% after phase III MAPLE-HCM results showed that aficamten outperformed metoprolol in obstructive HCM.
Wall Street Analysts Think CorMedix ( CRMD ) Could Surge 32.04%: Read This Before Placing a Bet
The mean of analysts' price targets for CorMedix (CRMD) points to a 32% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Editas Nominates EDIT-401 as Lead In Vivo Therapy for High Cholesterol
EDIT nominates EDIT-401, a one-time in vivo gene editing therapy, as its lead pipeline candidate to cut the risk of elevated cholesterol.
Is DefenCath Sufficient to Support CorMedix's Long-Term Growth Path?
CRMD's DefenCath, its only revenue source, posts $78.8M in sales in H1 2025, with exclusivity through 2033 fueling growth potential.
CorMedix Completes Acquisition of Melinta Therapeutics, Raises Financial Guidance and Announces New Leadership Team
- Transformational deal for CorMedix that expands and diversifies company's commercial product portfolio, with seven innovative drug products and a pipeline expansion indication with near-term revenue growth potential ...
CorMedix Completes Acquisition of Melinta Therapeutics, Raises Financial Guidance and Announces New Leadership Team - Cormedix ( NASDAQ:CRMD )
- Transformational deal for CorMedix that expands and diversifies company's commercial product portfolio, with seven innovative drug products and a pipeline expansion indication with near-term revenue growth potential -
ALNY/RHHBY's Zilebesiran to Enter Phase III After Third Phase II Win
Alnylam and Roche report positive phase II KARDIA-3 results for zilebesiran in high-risk hypertension patients, fueling momentum for a phase III study.
Biogen Secures FDA Nod for Subcutaneous Maintenance Dosing of Leqembi
BIIB wins FDA approval for Leqembi Iqlik, a fast, subcutaneous option for early Alzheimer's patients transitioning from IV infusions.
J&J Ends Imaavy Development in Rheumatoid Arthritis Post Study Failure
JNJ halts Imaavy's rheumatoid arthritis program after trial results showed no added benefit over existing therapy.
OTLK Stock Crashes 54% as FDA Issues Second CRL for Eye Disease Drug
Outlook Therapeutics stock plunges 54% after the FDA rejects ONS-5010 BLA again, citing lack of efficacy data in confirmatory study.
INO Stock Soars as FDA Backs Rolling BLA for Rare Lung Disease Drug
Inovio stock surges 21% after the FDA gives green light to begin a rolling BLA for its RRP drug INO-3107, with plans to seek priority review.
CorMedix to Participate in Upcoming Investor Conferences
BERKELEY HEIGHTS, N.J., Aug. 28, 2025 ( GLOBE NEWSWIRE ) -- CorMedix Inc. ( "CorMedix" ) ( Nasdaq: CRMD ) , a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced that senior management will be ...
CorMedix to Participate in Upcoming Investor Conferences - Cormedix ( NASDAQ:CRMD )
BERKELEY HEIGHTS, N.J., Aug. 28, 2025 ( GLOBE NEWSWIRE ) -- CorMedix Inc. ( "CorMedix" ) CRMD, a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced that senior management will be presenting and ...
Catalyst Pharmaceuticals Settles Firdapse Patent Litigation With Lupin
CPRX secures a key win as its Firdapse patent litigation settlement with Lupin shields U.S. sales from generic competition until 2035.
IOVA Stock Drops 6% on $350M Common Stock Offering
Iovance shares slid 6% after unveiling a $350 million stock offering, raising dilution concerns while funding growth plans for Amtagvi and its pipeline.
PGEN Stock Surges 144% in August on FDA Nod for Rare Lung Disease Drug
Precigen stock soars 144% in August after FDA approval of Papzimeos, the first treatment for adults with recurrent respiratory papillomatosis.
GILD Stock Slips as CVS Health Excludes New HIV Drug Yeztugo
Gilead shares slip after CVS refused to add its new HIV drug, Yeztugo, while its Kite unit struck a $350 million deal with Interius BioTherapeutics.
Is Adagene ( ADAG ) Outperforming Other Medical Stocks This Year?
Here is how Adagene Inc. Sponsored ADR (ADAG) and CorMedix (CRMD) have performed compared to their sector so far this year.
Wall Street Analysts Believe CorMedix ( CRMD ) Could Rally 45.63%: Here's is How to Trade
The average of price targets set by Wall Street analysts indicates a potential upside of 45.6% in CorMedix (CRMD). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Why CorMedix ( CRMD ) Might be Well Poised for a Surge
CorMedix (CRMD) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Kodiak Q2 Loss Wider Than Expected, Pipeline Development in Focus
KOD's Q2 loss widens as it ramps up clinical studies for three key eye disease treatments with pivotal data readouts planned.
Theravance's Q2 Loss Narrower Than Expected, Revenues Rise Y/Y
TBPH posts better-than-expected second-quarter 2025 results, boosted by Yupelri sales and licensing gains.
Time to Buy Eli Lilly and Other Undervalued Healthcare Stocks?
Eli Lilly, CorMedix and Johnson & Johnson represent a diversified mix of healthcare stocks with bullish catalysts ...
SMMT Q2 Loss Wider Than Expected, Ivonescimab Studies in Focus
Summit Therapeutics posts wider-than-expected second-quarter loss as ivonescimab trials advance in multiple lung cancer settings.
Immunovant's Q1 Loss Narrower Than Expected, Pipeline in Focus
IMVT reports a narrower Q1 loss, as spotlight remains on IMVT-1402's broad clinical potential across multiple indications.
